Proceedings from the fifth in a series of 11 integrated webinars
held in association with the 2020 ONS Annual Congress. Featuring
perspectives from Ms Paula J Anastasia, Ms Jennifer Filipi, Dr
David M O’Malley and Dr Shannon N Westin.
Introduction (00:00)
Mechanism of action of PARP inhibitors and integration into the
therapeutic algorithm for patients with advanced ovarian
cancer (OC) (5:16)
Efficacy and duration of maintenance therapy with olaparib or
niraparib in the Phase III SOLO-1 and PRIMA trials for patients
with OC in the first-line setting (13:01)
Response and tolerability with olaparib as
maintenance therapy for patients with advanced OC with BRCA
mutations (20:05)
Genetic testing for patients with OC; selection of
PARP inhibitor therapy (25:01)
Choice of PARP inhibitor alone or in combination with
bevacizumab as maintenance therapy for patients
with advanced OC (29:17)
Activity of olaparib as maintenance therapy for OC;
gastrointestinal and hematologic toxicities with PARP inhibitors
(34:49)
Role of immune checkpoint inhibitors in the treatment of
endometrial cancer; significance of microsatellite instability
(47:37)
Emerging data with pembrolizumab alone or in combination with
lenvatinib for endometrial cancer (54:48)
Dosing considerations and side effects with
pembrolizumab/lenvatinib (59:12)
Response to immune checkpoint inhibitors in patients with
cervical cancer (1:09:21)
Immune-related adverse events associated with checkpoint
inhibitors; considerations for the use of immune checkpoint
inhibitors in the COVID-19 era (1:14:34)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.